50 results about "Cytoprotective Agent" patented technology

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic / antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion. The present invention also relates to the use of one or more water soluble zinc salts, administered in combination with a therapeutic compound or agent (second therapeutic agent) which may be delivered orally with enhanced bioavailability (compared to compounds which are administered in the absence of water soluble zinc salts) or other favorable benefits. In addition, therapeutic agents which exhibit sensitivity to low pH may be advantageously orally administered in combination with an effective amount of at least one water soluble zinc salt. Compositions according to the present invention exhibit greater bioavailability of the active agent when formulated in combination with a water soluble zinc salt in oral dosage form than when administered with the water soluble zinc salt.

The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody / fragment which specifically binds to targeted organ, tissue or cell. The antibody / fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

There is disclosed a novel genus of small peptides, much smaller than human TGFα, was discovered as having TGFα biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGFα polypeptide. There is further disclosed that TGFα and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.

Compounds useful as antiproliferative agents, radioprotective agents and cytoprotective agents, including, for example, anticancer agents, are provided according to formula I: wherein ring A, ring B,,X, R1, R2, R3, a, and b are as defined herein.

The present invention provides preparations for efficaciously administering ginsenoside Rb1 or its salt useful as cytoprotective agents. More particularly, the present invention provides pharmaceutical compositions comprising ginsenoside Rb1 or its salt for inhibiting apoptosis or apoptosis-like cell death or pharmaceutical compositions comprising ginsenoside Rb1 or its salt for promoting the expression of a cell death-inhibitory gene product Bcl-xL. Further, the present invention provides preparations for intravenous administration comprising ginsenoside Rb1 or its salt. The above pharmaceutical compositions contain ginsenoside Rb1 or its salt at low extracellular concentrations in lesion, preferably at 1 ng / ml or less and still preferably at 1 to 100 fg / ml. These compositions promote the expression of the cell death-inhibitory gene product Bcl-xL and inhibit apoptosis or apoptosis-like cell death. The above preparations for intravenous administration are useful for therapy, prevention or treatment of many diseases, in particular, brain and nervous diseases.

The invention discloses a nano-compound and its preparation method and application in preparation of a chemotherapeutic drug cytoprotective agent and belongs to the technical field of biotechnology and biomedical materials. The nano-compound comprises a GC base pair-rich oligonucleotide and a gold nanocage. The end 3' of one chain in oligonucleotide is connected to the gold nanocage through a thiol group. The content of the GC base pairs in the oligonucleotide is greater than 50%. The nano-compound Au-ODN can enter cytoplasm through endocytosis, can capture the chemotherapeutic drug entering the cell, and can inhibit the effect of the drug entering the nucleus. 70-80% of the nano-compound can target liver tissue, and only about 5% of the nano-compound can enter cancer tissue. Therefore, the nano-compound Au-ODN can be used for preparing a chemotherapeutic drug cytoprotective agent for preventing liver cells from being damaged by drugs and has no influence on the anti-tumor effect of the chemotherapy drugs.

There is disclosed a novel genus of small peptides, smaller than human TGFα, identified as having TGFα biological activity and therefore being useful as pharmacologic agents. It is further disclosed that both TGFα and the genus of small peptides disclosed herein have therapeutic activity to stimulate hematopoiesis, e.g., in patients undergoing cytotoxic cancer chemotherapy, and also act as cytoprotective agents to protect patients undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis, and otherwise to support the barrier function of the GI tract, such as when it is harmed by cytotoxic therapy.

Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.

The invention discloses cell protective agent containing metallothionein, which aims to solve the problems that blood cells are damaged during blood perfusion, corresponding tissues and organs during growth are damaged after the cells are cultured and augmented in vitro and transplanted and survival rate is low and the like, and can be used for blood perfusion treatment method and cell treatment method including a method for protecting the corresponding tissues and organs after vitro-culturing, augmenting and transplanting of the cells. The cell protective containing metal sulfur protein can be widely used for protecting blood cells of human bodies with diseases such as uremia, critical illness, intoxication, systemic lupus erythematosus (SLE), severe hepatitis and the like during blood perfusion treatment, and protecting corresponding cultured and augmented cells or transplanted and hyperplasia cells of the corresponding tissues and organs in the cell treatment of diseases caused by severe damage or reduction of the cells.

The invention provides a microbe sample preservation solution for gene detection, a preparation method and a kit thereof, and an application of the kit, and belongs to the technical field of bioengineering. The microbe sample preservation solution for gene detection has effective and comprehensive microbe inactivation capability; and low-concentration ethanol is used to thoroughly inactivate bacteria in the storage process of a sample, and avoids inactivation failure caused by the stress reaction of bacteria due to high-concentration ethanol. The microbe sample preservation solution has good permeability on the premise of not destroying the cell structure, and effectively destroys the protein activity of bacteria and viruses and the activities of various nucleases to make the bacteria, viruses and nucleases not have of infection or proliferation ability, so the thorough inactivation effect is achieved. A glycerol-containing cytoprotective agent and a physiological concentration buffersolution are used to keep the cell structure of microbes and prevent the cell structure from be ruptured in order to protect the integrity of nucleic acids in cells; and the microbe sample preservation solution contains no high-toxicity components or volatile components, so no volatile poisoning occurs during use.

The endopeptidase hydrolysis of cross link peptide bond of the peptidoglycans results in release of the novel glucosaminemuramyl tri, tetra, penta, hexa, and octapeptides. Their structure is defined by specific endopeptidase cleavage as well as genus of gram positive bacteria. They are potent cytoprotective agents capable of inhibiting of TNF alpha cytotoxicity.

Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.

The present invention relates generally to the use of γ-glutamyl antioxidants, particularly γ-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The γ-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the reverse movement of Na / Ca exchange in the blood-brain barrier such as 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulphonate (KB-R7943).

Disclosed is a prophylactic or therapeutic agent for nerve diseases such as ischemic brain diseases and neurodegenerative diseases or the like or a prophylactic or therapeutic agent for diseases for which an antioxidant activity is effective, which can act as a cell-protecting agent, particularly an inhibitor of cerebral cell injury or cerebral cell death. Specifically disclosed is a compound represented by formula (1), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof. The formula (1) is shown in the description.

An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentration, decreased attention, decreased judgment ability, depression, and decreased exercise performance caused thereby. According to the present invention, an agent for protecting brain neuronal cells, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients as well as an agent for preventing or improving decline in brain function, comprising citrulline or a salt thereof and citicoline or a salt thereof as active ingredients is provided.

The invention relates to the technical field of medical detection, and discloses a vagina microorganism immunofluorescence staining solution. Comprising the following raw materials in parts by weight: 5-8 parts of a fluorescent coloring agent, 2-3 parts of an auxiliary dye, 1-3 parts of a stabilizer, 1-3 parts of a penetrant, 2-5 parts of a bacteriostatic agent, 1-2 parts of an anti-quenching agent, 2-4 parts of a permeable agent, 2-4 parts of a buffer solution, 5-6 parts of a cell protective agent and 20-40 parts of purified water. According to the vagina microbial immunofluorescence staining solution, the stability of the fluorescent staining solution during staining can be improved by adding the stabilizer, the fluorescence retention time is prolonged, the problem that the staining fluorescence is not obvious due to poor staining stability and the detection data is influenced is avoided, and meanwhile, the antibacterial activity of the fluorescent staining solution is improved by adding the bacteriostatic agent; the fluorescent staining solution can be stored for a longer time, the permeability agent and the penetrant added in the fluorescent staining solution can improve the permeability to cell membranes, staining of cells by fluorescein can be accelerated, and the practicability of the vagina microbial immunofluorescence staining solution is enhanced.

The present disclosure relates to the field of cytobiology and modulation of cellular mechanisms to control cell viability, cell proliferation and metabolic processes. More specifically, disclosed herein are peptides that are effective in modulating cellular mechanisms that control cell viability, cell proliferation and metabolic processes, including cellular signaling associated with abnormal cell proliferation and malignant diseases. Also disclosed herein are peptides that effectively modulate cellular mechanisms that control cell viability, treat metabolic diseases, and act as cytoprotective agents. Also disclosed herein are peptides useful as apelin receptor agonists.

The present invention provides medicinal or pharmaceutical compositions and preparations for administration, which are useful as cytoprotective agents and a remedy for neurotrauma, comprising ginseng, its extract, ginseng components, metabolites thereof or salts thereof (for example, red ginseng powder or components thereof). More particularly, the present invention provides medicinal or pharmaceutical compositions for inhibiting apoptosis or apoptosis-like cell death, medicinal or pharmaceutical compositions for promoting the expression of a cell death-suppressing gene product BCl-xL, or preparations for oral or intravenous administration, comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof preferably at low concentrations. These medicinal or pharmaceutical compositions and / or preparations for administration are characterized by containing, as the active ingredient(s), ginseng, its extracts, ginseng components, metabolites thereof or salts thereof at low concentrations. These drugs are useful for therapy, prevention or treatment of brain and nervous diseases, heart diseases, etc.

The invention provides an improved mesenchymal stem cell protective solution. The concentration of electrolytes in an unfrozen water solution inside and outside cells is balanced through a permeatingprotective agent, so that cell damage due to excessive dehydration of cells in the outside high-permeability environment is avoided; added protein composition can supply cells with required nutrients,and accordingly, the cell survival rate is increased; a physiological activity inhibitor of cells can reversibly inhibit physiological activities in the cells, and the cryopreservation effect is improved on the premise that the cell activity is not affected; amifostine is a broad-spectrum cell protective agent and a radiation protective agent and can improve the tolerance of cells to the outsideadverse environment, reduce accumulation of toxic substances in cells and improve the proliferative activity of stem cells. Through combined use of components, the stress resistance of mesenchymal stem cells can be effectively improved, cell activity loss caused in the cryopreservation process can be reduced, and the cell survival rate and the thawing rate after cryopreservation are increased.